IJCRT.ORG ISSN : 2320-2882

INTERNATIONAL JOURNAL OF CREATIVE RESEARCH THOUGHTS (IJCRT)

An International Open Access, Peer-reviewed, Refereed Journal

Nanotechnology In Cancer Drug Delivery: A Revolutionary Approach To Targeted Therapy

Pratik.A.Ugare, Snehal.M.Jadhav, Sanskruti.S.Desai.

Assistant professor, Student, Student
Department of pharmaceutics,
Dr.J.J. Magdum pharmacy college, Jaysingpur.

Abstract: Nanotechnology has introduced groundbreaking advancements in oncology by revolutionizing how anticancer agents are delivered. Conventional chemotherapy faces challenges like poor selectivity and severe systemic toxicity. Nanocarrier-based drug delivery systems—including liposomes, dendrimers, polymeric particles, micelles, and metallic nanoparticles—enable site-specific drug accumulation, enhance bioavailability, and minimize adverse effects. This review comprehensively examines key nanotechnology principles in cancer treatment, types of Nano systems, FDA-approved nano formulations, and emerging innovations, underscoring their transformative role in targeted cancer therapy.

Keywords - Cancer therapy, Nanotechnology, Nanocarriers, Targeted drug delivery, Liposomes, Chemotherapy, Oncology.

1. Introduction –

Cancer is among the most prevalent causes of mortality worldwide. Traditional anticancer therapies, such as chemotherapy, often lack specificity, leading to damage in healthy tissues and undesirable side effects. Nanotechnology has emerged as a powerful solution to these limitations, offering drug formulations with improved solubility, enhanced stability, and selective tumor accumulation. Nanomedicine leverages nanoscale carriers to transport drugs directly to tumor sites, thereby improving efficacy and minimizing collateral toxicity.

The Significance of Nanotechnology in Cancer Drug Administration -

- Traditional Therapy's Drawbacks Drug distribution that is not selective harms healthy cells. Frequent dosage will result from a short circulation half-life. Poor solubility is a common feature of hydrophobic medicines. Mechanisms of resistance, such as efflux pumps, are developed by tumors.

- The Way Nanotechnology Handles These Problems Optimal size: Nanoparticles (~10–200 nm) can enter the tumour's leaky vascular system (EPR impact). Surface modification: Through ligand-receptor interaction, it improves tumor targeting. Reduced dose frequency and improved pharmacokinetics are two benefits of controlled release. Multifunctionality: At the same time, nanoparticles can transport genes, imaging agents, and many medications.

Challenges in Standard Chemotherapy -

- Non-selective biodistribution
- Inadequate solubility of hydrophobic drugs
- Resistance mechanisms including multidrug resistance (MDR)

2. The Drawbacks of Traditional Chemotherapy -

Non-specific allocation
Low solubility
Resistance to multiple drugs (MDR)
Advantages of nanotechnology
A higher level of tumor selectivity
Consistent and regulated medication release
Decreased toxicity

3. Benefits of Nanotechnology-

- Specific accumulation in tumor tissues
- Sustained and controlled release kinetics
- Lower toxicity to healthy cells
- Enhanced therapeutic index

4. Fundamentals of Nanotechnology-Based Cancer Treatments -

4.1 The EPR Effect and Passive Tumor Targeting Limited lymphatic drainage and leaky vasculature are characteristics of cancerous tissues. Because of these anatomical anomalies, nanoparticles (usually ranging in size from 10 to 200 nm) can aggregate in tumor areas more easily than in healthy tissues due to the increased permeability and retention (EPR) effect.

4.2 Surface Modification for Active Targeting Biological ligands like peptides, antibodies, or aptamers can be used to functionalize nanocarriers. These ligands enhance cellular uptake and therapeutic precision by selectively binding to overexpressed receptors on cancer cells, such as HER2, transferrin, and folate.

Nanocarrier Systems Used in Cancer Treatment -

3.1 phospholipids for the treatment of cancer. Hydrophilic or hydrophobic drugs can be included. For example, doxylis, a pegylated liposomal doxorubicin, is used to treat breast and ovarian cancer.

3.2 Polymer nanoparticles from PLGA and other biodegradable polymers. Restrict treatment and release longer. This material can be used under the use of peptides or antibodies.

3.3 The dendrimer structure is uniform and highly branched. It has a terminal group for the target and an internal cave for the stress of the drug. Enter precise controls for surface chemistry and size.

3.4 Nanoparticles made of metal oxide iron and gold nanoparticles are used in both therapeutic and diagnostic applications. Local warmth can be produced in response to external stimuli such as light or magnetic fields.

3.5 micelles and nanospheres are advantageous for drug therapy solutions that are not very soluble in water. Create a core-shell structure by implementing yourself in an aquatic environment

In Table Format –

Nanocarrier type	Feature	Example	Advantages
Liposome	Phospholipid vesicles	Doxil	Biocompatible, flexible, payload (hydrophilic and Hydrophobic)
Polymeric NPs	Biodegradable polymer (E.g. – PLGA, PEG)	Genexol-PM	Controlled release stable in circulation
Micelles	Self-assembled amphiphilic molecules	NK105	Enhanced solubility of hydrophobic drug
Dendrimers	Branched, monodisperse polymer	PAMAM	High drug – loading potential, modifiable surface
Metallic/ Magnetic NPs	Gold, Silver, Iron, Oxide- based	Auroshell	Imaging, hyperthermia, targeted therapy

5. Target Preparation Strategy -

5.1 Passive Targeting –

Target the need for specific ligands using the intrinsic physiology of tumor vessel systems for nanocore development in malignant regions.

5.2Ligand-Directed Active Targeting –

Active ligand-oriented goals increase the absorption and selectivity of Nani Carter by binding to specific cancer cell antigens using ligands (such as folic acid or monoclonal antibodies).

5.3 Stimuli-Sensitive Delivery System –

Taxation in response to stimuli in the tumor environment responds to intellectual nomocracies to external (temperature, magnetic field) or endogenous **(pH, enzymes, redox) stimuli that are made possible for locally specific drug release.**

6. Nanotechnology's Advantages for Cancer Treatment -

- Enhanced ability to target cancerous areas
- Preventing early degradation of therapeutic agents
- Capacity to overcome resistance to drugs
- Combining imaging techniques (theranostics)
- Decrease in unintended adverse effects

1. Better Drug Solubility: Increases the bioavailability of medications that are not very soluble.
2. Targeted Delivery: Promotes drug accumulation at the tumor location and decreases off-target effects.
3. Sustained Release: Preserves therapeutic levels for a long time.
4. Combination therapy allows for the co-administration of many medications or therapeutic agents.
5. Theranostic Applications: Used in both imaging and therapy.

7. **Restrictions and Difficulties -**

1) Complexity in reproducible formulation and large-scale production
2) Limited information on non-biodegradable materials' long-term safety
3) Regulatory obstacles brought on by new systems
4) High development and commercialization expenses
5) Possible issues with immunogenicity and bioaccumulation

8. **Future Paths-**

8.1 Customized Nanomedicine Nanoparticle compositions can be tailored for specific patients based on their genetic and molecular characteristics.

8.2 Integration of CRISPR-Cas9 and Gene Therapy Utilizing nanoparticles to deliver gene-editing tools to fix mutations that cause cancer.

8.3 Nanomedicine and Artificial Intelligence optimizing therapy prediction, targeting precision, and nanoparticle design with the use of AI and machine learning.

8.4 The use of nanomedicine delivering immune cells, vaccinations, or immune checkpoint inhibitors straight to tumors via nanocarriers.

Conclusion –

The development of sophisticated medication delivery systems made possible by nanotechnology has fundamentally changed the landscape of cancer treatment. These nanoscale carriers provide accurate cancer cell targeting, maximizing therapeutic effectiveness while reducing damage to healthy tissues. This focused strategy lessens toxicity and systemic damage, two common adverse effects of traditional chemotherapy, increasing treatment efficacy and patient safety.

Regulatory permissions, production scalability, and cost are some of the challenges associated with integrating nanotechnology into clinical practice; nevertheless, these are being addressed by continual advancements in materials science and biomedical engineering. Advances in surface modification, nanoparticle design, and biocompatibility are making it easier to develop more intelligent and individualized drug delivery systems.

Nanotechnology-based systems are anticipated to advance in the future as scientists get a deeper understanding of tumor biology and the tumor microenvironment. An important step toward genuinely personalized oncology will likely be made possible by these developments, which will allow for highly customized treatments based on each patient's unique genetic and molecular profile.

References -

1. Barenholz, Y. (2012). Doxil®—The first FDA-approved nano-drug: Lessons learned. Journal of Controlled Release, 160(2), 117–134.
2. Koo, H., et al. (2012). Targeted delivery of nanoparticles for anticancer therapy. Nature Nanotechnology, 7(9), 676–687.
3. Shi, J., et al. (2017). Cancer nanomedicine: Progress, challenges and opportunities. Nature Reviews Cancer, 17(1), 20–37.
4. Peer, D., et al. (2007). Nanocarriers as an emerging platform for cancer therapy. Nature Nanotechnology, 2(12), 751–760.
5. Sanna, V., et al. (2014). Targeted therapy using nanotechnology. Pharmacological Research, 86, 1–10.